Published in Am J Epidemiol on October 26, 2010
Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis (2014) 6.80
Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel. BMC Med (2016) 1.46
Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol (2013) 1.44
Poliomyelitis outbreak, Pointe-Noire, Republic of the Congo, September 2010-February 2011. Emerg Infect Dis (2011) 1.39
The role of research in viral disease eradication and elimination programs: lessons for malaria eradication. PLoS Med (2011) 1.34
Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence. Viruses (2011) 1.08
Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. BMC Infect Dis (2015) 1.03
The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis (2014) 1.01
High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies. Clin Vaccine Immunol (2012) 0.96
High-Throughput Next Generation Sequencing of Polioviruses. J Clin Microbiol (2016) 0.91
Unraveling the Transmission Ecology of Polio. PLoS Biol (2015) 0.90
Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria. PLoS One (2015) 0.88
Extracting transmission networks from phylogeographic data for epidemic and endemic diseases: Ebola virus in Sierra Leone, 2009 H1N1 pandemic influenza and polio in Nigeria. Int Health (2015) 0.87
Deficiency of immunity to poliovirus type 3: a lurking danger? BMC Infect Dis (2012) 0.86
The double-edged sword: How evolution can make or break a live-attenuated virus vaccine. Evolution (N Y) (2011) 0.86
Adjuvants and inactivated polio vaccine: a systematic review. Vaccine (2012) 0.83
An epidemiological analysis of acute flaccid paralysis and its surveillance system in Iraq, 1997-2011. BMC Infect Dis (2014) 0.82
Evolutionarily stable attenuation by genome rearrangement in a virus. G3 (Bethesda) (2013) 0.82
The microbiology of human hygiene and its impact on type 1 diabetes. Islets (2012) 0.81
Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proc Natl Acad Sci U S A (2014) 0.81
A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine (2013) 0.80
Poliomyelitis in transgenic mice expressing CD155 under the control of the Tage4 promoter after oral and parenteral poliovirus inoculation. J Gen Virol (2014) 0.79
Evolutionary reversion of live viral vaccines: Can genetic engineering subdue it? Virus Evol (2015) 0.79
Re: "From emergence to eradication: the epidemiology of poliomyelitis deconstructed". Am J Epidemiol (2011) 0.78
Direct Identification of Enteroviruses in Cerebrospinal Fluid of Patients with Suspected Meningitis by Nested PCR Amplification. Viruses (2016) 0.78
Has Wild Poliovirus Been Eliminated from Nigeria? PLoS One (2015) 0.77
A spatial model of Wild Poliovirus Type 1 in Kano State, Nigeria: calibration and assessment of elimination probability. BMC Infect Dis (2016) 0.77
Detection of imported wild polioviruses and of vaccine-derived polioviruses by environmental surveillance in Egypt. Appl Environ Microbiol (2012) 0.76
Direct Detection and Identification of Enteroviruses from Faeces of Healthy Nigerian Children Using a Cell-Culture Independent RT-Seminested PCR Assay. Adv Virol (2016) 0.76
Acute flaccid paralysis surveillance indicators in the Democratic Republic of Congo during 2008-2014. Pan Afr Med J (2016) 0.75
Molecular characterization and phylogenetic relationship of wild type 1 poliovirus strains circulating across Pakistan and Afghanistan bordering areas during 2010-2012. PLoS One (2014) 0.75
Largest reservoir of Polio virus in the world--the elusive way forward! Pathog Glob Health (2014) 0.75
An epidemiological analysis of acute flaccid paralysis in Khuzestan Province, southwest Iran, from 2006 to 2010. Epidemiol Health (2016) 0.75
Eradication and Current Status of Poliomyelitis in Pakistan: Ground Realities. J Immunol Res (2016) 0.75
Abrupt transition to heightened poliomyelitis epidemicity in England and Wales, 1947-1957, associated with a pronounced increase in the geographical rate of disease propagation. Epidemiol Infect (2013) 0.75
Polio elimination in Nigeria: A review. Hum Vaccin Immunother (2016) 0.75
Support for children identified with acute flaccid paralysis under the global polio eradication programme in Uttar Pradesh, India: a qualitative study. BMC Public Health (2012) 0.75
Putting together the pieces of polio: how Dorothy Horstmann helped solve the puzzle. Yale J Biol Med (2011) 0.75
Defining the Enterovirus Diversity Landscape of a Fecal Sample: A Methodological Challenge? Viruses (2016) 0.75
Contribution of Contact Sampling in Increasing Sensitivity of Poliovirus Detection During A Polio Outbreak-Somalia, 2013. Open Forum Infect Dis (2016) 0.75
Vaccine-preventable infections in Systemic Lupus Erythematosus. Hum Vaccin Immunother (2016) 0.75
Eradicating infectious disease using weakly transmissible vaccines. Proc Biol Sci (2016) 0.75
Neuroepidemiology and the epidemiology of viral infections of the nervous system. Handb Clin Neurol (2014) 0.75
Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release. J Control Release (2016) 0.75
A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus. J Virol (2016) 0.75
Treatment of perinatal viral infections to improve neurologic outcomes. Pediatr Res (2016) 0.75
Physiotherapy for poliomyelitis: a descriptive study in the Republic of Congo. BMC Res Notes (2014) 0.75
Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Rev Vaccines (2015) 0.75
Spatial model for risk prediction and sub-national prioritization to aid poliovirus eradication in Pakistan. BMC Med (2017) 0.75
Pathogenic events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis. J Virol (2017) 0.75
Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems. Food Environ Virol (2017) 0.75
Custom rotating hinge total knee arthroplasty in patients with poliomyelitis affected limbs. Int Orthop (2014) 0.75
Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog (2007) 8.61
Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science (2002) 5.71
Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol (2005) 4.42
Geographic distribution of wild poliovirus type 1 genotypes. Virology (1987) 4.03
Poliomyelitis in the world. Bull World Health Organ (1970) 3.89
Eradication versus control for poliomyelitis: an economic analysis. Lancet (2007) 3.73
Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet (2007) 3.73
Present position of immunization against poliomyelitis with live virus vaccines. Br Med J (1959) 3.55
Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA (1960) 3.40
New strategies for the elimination of polio from India. Science (2006) 3.27
Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol (1999) 3.16
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis (1992) 3.07
Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet (2005) 3.01
The principles of disease elimination and eradication. Bull World Health Organ (1998) 2.63
Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA (2004) 2.60
Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis (1992) 2.55
Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health Nations Health (1954) 2.39
Pathogenesis of poliomyelitis; reappraisal in the light of new data. Science (1956) 2.37
Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA (1987) 2.28
Emerging concept of poliomyelitis infection. Science (1955) 2.26
Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol (1998) 2.24
Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med (2010) 2.21
Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period; the ratio of inapparent infection to clinical poliomyelitis. Am J Hyg (1953) 2.13
Polio today: are we on the verge of global eradication? JAMA (2008) 1.98
Poliomyelitis distribution in the United States. Public Health Rep (1953) 1.93
Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ (2004) 1.90
Developing gap in immunity to poliomyelitis in an urban area. JAMA (1969) 1.89
The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol (1979) 1.87
Virus survival as a seasonal factor in influenza and poliomylitis. Antonie Van Leeuwenhoek (1962) 1.86
Resurgence of wild poliovirus type 1 transmission and consequences of importation--21 countries, 2002-2005. MMWR Morb Mortal Wkly Rep (2006) 1.85
Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol (2008) 1.85
The molecular biology of poliovaccines. J Gen Virol (1992) 1.75
Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. J Virol (2000) 1.71
The incubation period of poliomyelitis. Am J Public Health Nations Health (1952) 1.69
Visualizing geographic and temporal trends in rotavirus activity in the United States, 1991 to 1996. National Respiratory and Enteric Virus Surveillance System Collaborating Laboratories. Pediatr Infect Dis J (1997) 1.67
Poliomyelitis in New York City, 1949. N Y State J Med (1950) 1.63
One hundred years of poliovirus pathogenesis. Virology (2006) 1.59
New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis (2008) 1.58
Cuba: mass polio vaccination program, 1962-1982. Rev Infect Dis (1984) 1.57
Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N Engl J Med (2008) 1.57
Incidence of poliomyelitis since 1920. Monogr Ser World Health Organ (1955) 1.56
A survey of poliomyelitis virus antibodies in French Morocco. Am J Trop Med Hyg (1955) 1.55
Polio eradication. Looking for a little luck. Science (2009) 1.55
Vaccine-associated poliomyelitis in the United States, 1961-1972. Am J Epidemiol (1976) 1.54
The role of routine polio immunization in the post-certification era. Bull World Health Organ (2004) 1.53
Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int J Epidemiol (2001) 1.53
Relation of poliomyelitis virus types to clinical disease and geographic distribution: a preliminary report. Ann N Y Acad Sci (1955) 1.52
The control of poliomyelitis in Brazil. Rev Infect Dis (1984) 1.52
A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Lond) (1966) 1.51
Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med (2008) 1.49
Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event. Virus Res (2005) 1.44
Magnitude of problem of poliomyelitis in India. Indian Pediatr (1981) 1.44
PARALYTIC DISEASE ASSOCIATED WITH ORAL POLIO VACCINES. JAMA (1964) 1.43
Eradication of poliomyelitis in the United States. Rev Infect Dis (1983) 1.42
Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet (2004) 1.33
Wild poliovirus type 1 and type 3 importations--15 countries, Africa, 2008-2009. MMWR Morb Mortal Wkly Rep (2009) 1.23
Resolution of the pathways of poliovirus type 1 transmission during an outbreak. J Clin Microbiol (2000) 1.23
Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988-1995. J Infect Dis (1997) 1.22
Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep (2001) 1.22
Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis (2010) 1.19
Disease eradication as a public health strategy: a case study of poliomyelitis eradication. Bull World Health Organ (2000) 1.18
Certification of poliomyelitis eradication--the Americas, 1994. MMWR Morb Mortal Wkly Rep (1994) 1.18
Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec (2010) 1.16
Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients. Infect Immun (1982) 1.14
Update on vaccine-derived polioviruses--worldwide, January 2008-June 2009. MMWR Morb Mortal Wkly Rep (2009) 1.13
The pathogenesis of poliomyelitis: what we don't know. Adv Virus Res (2008) 1.12
Vaccination against poliomyelitis in economically underdeveloped countries. Bull World Health Organ (1980) 1.12
The changing age distribution of paralytic poliomyelitis. Ann N Y Acad Sci (1955) 1.12
Vaccination against polio should not be stopped. Nat Rev Microbiol (2007) 1.10
Estimating the extent of vaccine-derived poliovirus infection. PLoS One (2008) 1.05
Interrupting poliovirus transmission -- new solutions to an old problem. Biologicals (2006) 1.03
Certification of poliomyelitis eradication. WHO Western Pacific Region, October 2000. Wkly Epidemiol Rec (2000) 1.03
Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec (2006) 1.01
Status of the eradication of indigenous wild poliomyelitis in the People's Republic of China. J Infect Dis (1997) 1.00
Vaccine-derived polioviruses. Biologicals (2006) 0.97
Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. Int J Epidemiol (2003) 0.97
Immunologic classification of poliomyelitis viruses. I. A cooperative program for the typing of one hundred strains. Am J Hyg (1951) 0.96
Laboratory surveillance for wild and vaccine-derived polioviruses - worldwide, January 2008-June 2009. MMWR Morb Mortal Wkly Rep (2009) 0.96
Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management. Risk Anal (2006) 0.95
The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health (2008) 0.94
Immunisation against poliomyelitis: moving forward. Lancet (2008) 0.93
Virology. Poliomyelitis eradication--a dangerous endgame. Science (2002) 0.91
Poliomyelitis in Tajikistan: first importation since Europe certified polio-free. Wkly Epidemiol Rec (2010) 0.91
The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. Virology (2000) 0.90
A vision of a world without polio: the OPV cessation strategy. Biologicals (2006) 0.89
The epidemiology of paralytic poliomyelitis in Hawaii. Hawaii Med J (1954) 0.89
Surveillance for polio eradication in the People's Republic of China. J Infect Dis (1997) 0.86
Perspective: determinants of the severity of poliovirus outbreaks in the post eradication era. Risk Anal (2006) 0.85
Progress towards interruption of wild poliovirus transmission worldwide, 2009. Wkly Epidemiol Rec (2010) 0.85
Poliovirus neutralizing antibody levels among preschool children. Public Health Rep (1968) 0.85
Differentiation of types of poliomyelitis viruses; reinfection experiments in monkeys (second attacks). Am J Hyg (1949) 0.83
Polio control after certification: major issues outstanding. Bull World Health Organ (2004) 0.83
Certification of poliomyelitis eradication. Wkly Epidemiol Rec (2002) 0.82
Is there an ethical obligation to complete polio eradication? Lancet (2010) 0.80
The incubation period in human poliomyelitis and its implications. J Am Med Assoc (1947) 0.79
Progress towards eradicating poliomyelitis in Nigeria, January 2009- June 2010. Wkly Epidemiol Rec (2010) 0.79
The epidemiology of poliomyelitis in Burma. Dev Biol Stand (1981) 0.78
Risk of paralytic and nonparalytic forms of poliomyelitis to household contacts in nonepidemic years. N Engl J Med (1955) 0.78
Progress towards eradicating poliomyelitis in Afghanistan and Pakistan, 2009. Wkly Epidemiol Rec (2010) 0.78
Epidemiologic aspects of poliomyelitis eradication. Rev Infect Dis (1984) 0.77
Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA (2004) 2.60
Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol (2009) 2.01
Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ (2004) 1.28
Possible eradication of wild poliovirus type 3--worldwide, 2012. MMWR Morb Mortal Wkly Rep (2014) 1.27
Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt. Am J Epidemiol (2003) 1.26
Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J Virol (2003) 1.26
A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol (2005) 1.25
Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China. J Virol (2003) 1.25
Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis (2009) 1.18
Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal (2006) 1.10
Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal (2013) 1.10
Polio eradication: the OPV paradox. Rev Med Virol (2003) 1.07
Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015. MMWR Morb Mortal Wkly Rep (2015) 1.07
Estimating the extent of vaccine-derived poliovirus infection. PLoS One (2008) 1.05
Multiplex PCR method for identifying recombinant vaccine-related polioviruses. J Clin Microbiol (2004) 1.01
Environmental surveillance of wild poliovirus circulation in Egypt--balancing between detection sensitivity and workload. J Virol Methods (2005) 0.96
Polio-free certification and lessons learned--South-East Asia region, March 2014. MMWR Morb Mortal Wkly Rep (2014) 0.96
The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health (2008) 0.94
Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. J Clin Virol (2007) 0.93
Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d'Ivoire. J Infect Dis (2005) 0.91
Update on vaccine-derived polioviruses - worldwide, July 2012-December 2013. MMWR Morb Mortal Wkly Rep (2014) 0.88
Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management. Risk Anal (2008) 0.83
Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling. Risk Anal (2006) 0.81
Poliovirus vaccines: past, present, and future. Arch Pediatr Adolesc Med (2011) 0.79
Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary. Am J Epidemiol (2011) 0.77
Complete genome sequence of the last representative genotype of wild indigenous poliovirus type 1, which circulated in Brazil. Genome Announc (2013) 0.75
Molecular epidemiology of wild poliovirus type 1 circulation in West and Central Africa, from 1997 to 1999, using genotyping with a restriction fragment length polymorphism assay. Arch Virol (2007) 0.75